Skip to content

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04301752
Enrollment
82
Registered
2020-03-10
Start date
2019-02-01
Completion date
2020-03-01
Last updated
2020-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis

Keywords

Brucellosis, neuropsychiatric manifestations, cognition

Brief summary

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries. Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

Detailed description

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries. Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations. The aimed is to shed light to the obscure areas of diagnosis in neurobrucellosis and have detailed general and neurologic features

Interventions

DIAGNOSTIC_TESTMoCA

Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.

Sponsors

Mansoura University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years of age with laboratory-confirmed brucellosis

Exclusion criteria

* Previous neuropsychiatric disease

Design outcomes

Primary

MeasureTime frameDescription
MoCA s24 hoursCognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26 .

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026